Systemic corticosteroids (CS) should be considered as first-line treatment for acute asthma exacerbations, especially severe exacerbations. They may sometimes require a few hours or more to ...

Specifically, Dupixent is approved to treat moderate to severe asthma that is either: dependent on treatment with an oral corticosteroid, or eosinophilic (caused by an increase in eosinophils ...

Community-acquired pneumonia (CAP) is a systemic disease and continues to be the leading cause of infectious mortality ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

For many people suffering from asthma, the winter months and the colder air can trigger asthma symptoms and flare-ups, which ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

Conventional treatments for allergic rhinitis may also improve asthma outcomes in patients with both conditions. Read now!

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...